JP2018513175A - 非アルコール性脂肪性肝炎の予防および／または治療における（４−ヒドロキシ−２−メチル−１，１−ジオキシド−２Ｈ−ベンゾ［ｅ］［１，２］チアジン−３−イル）（ナフタレン−２−イル）メタノンの使用 - Google Patents

非アルコール性脂肪性肝炎の予防および／または治療における（４−ヒドロキシ−２−メチル−１，１−ジオキシド−２Ｈ−ベンゾ［ｅ］［１，２］チアジン−３−イル）（ナフタレン−２−イル）メタノンの使用 Download PDF

Info

Publication number
JP2018513175A
JP2018513175A JP2017555239A JP2017555239A JP2018513175A JP 2018513175 A JP2018513175 A JP 2018513175A JP 2017555239 A JP2017555239 A JP 2017555239A JP 2017555239 A JP2017555239 A JP 2017555239A JP 2018513175 A JP2018513175 A JP 2018513175A
Authority
JP
Japan
Prior art keywords
compound
benzo
dioxide
methyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017555239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513175A5 (enExample
Inventor
マリー、ラモト
ディディエ、ジュンケロ
ブルーノ、ル、グラン
Original Assignee
ピエール、ファーブル、メディカマン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン
Publication of JP2018513175A publication Critical patent/JP2018513175A/ja
Publication of JP2018513175A5 publication Critical patent/JP2018513175A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2017555239A 2015-04-21 2016-04-20 非アルコール性脂肪性肝炎の予防および／または治療における（４−ヒドロキシ−２−メチル−１，１−ジオキシド−２Ｈ−ベンゾ［ｅ］［１，２］チアジン−３−イル）（ナフタレン−２−イル）メタノンの使用 Pending JP2018513175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1553574 2015-04-21
FR1553574A FR3035326B1 (fr) 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
PCT/EP2016/058760 WO2016169983A1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Publications (2)

Publication Number Publication Date
JP2018513175A true JP2018513175A (ja) 2018-05-24
JP2018513175A5 JP2018513175A5 (enExample) 2019-05-30

Family

ID=53484018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017555239A Pending JP2018513175A (ja) 2015-04-21 2016-04-20 非アルコール性脂肪性肝炎の予防および／または治療における（４−ヒドロキシ−２−メチル−１，１−ジオキシド−２Ｈ−ベンゾ［ｅ］［１，２］チアジン−３−イル）（ナフタレン−２−イル）メタノンの使用

Country Status (12)

Country Link
US (1) US20180140609A1 (enExample)
EP (1) EP3285774B1 (enExample)
JP (1) JP2018513175A (enExample)
KR (1) KR20170139030A (enExample)
CN (1) CN107530355A (enExample)
AU (1) AU2016251601A1 (enExample)
BR (1) BR112017021586A2 (enExample)
CA (1) CA2981933A1 (enExample)
FR (1) FR3035326B1 (enExample)
MX (1) MX2017013453A (enExample)
RU (1) RU2017137262A (enExample)
WO (1) WO2016169983A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102177304B1 (ko) 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
RU2706026C1 (ru) * 2018-12-28 2019-11-13 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528308A (ja) * 2001-03-23 2004-09-16 ザ ユニバーシティ オブ エディンバラ 脂質プロフィールのモジュレーション
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体
KR20110060653A (ko) * 2009-11-30 2011-06-08 한국화학연구원 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
JP2011213685A (ja) * 2010-04-01 2011-10-27 Kowa Co ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
JP2012519203A (ja) * 2009-03-03 2012-08-23 ピエール、ファーブル、メディカマン ベンゾチアジン誘導体、それらの製造および薬剤としてのそれらの応用
WO2012144478A1 (ja) * 2011-04-19 2012-10-26 第一三共株式会社 テトラヒドロチアゼピン誘導体
JP2013527162A (ja) * 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528308A (ja) * 2001-03-23 2004-09-16 ザ ユニバーシティ オブ エディンバラ 脂質プロフィールのモジュレーション
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体
JP2012519203A (ja) * 2009-03-03 2012-08-23 ピエール、ファーブル、メディカマン ベンゾチアジン誘導体、それらの製造および薬剤としてのそれらの応用
KR20110060653A (ko) * 2009-11-30 2011-06-08 한국화학연구원 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
JP2011213685A (ja) * 2010-04-01 2011-10-27 Kowa Co ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
JP2013527162A (ja) * 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類
WO2012144478A1 (ja) * 2011-04-19 2012-10-26 第一三共株式会社 テトラヒドロチアゼピン誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
STEFAN NORBERT; ET AL: "INHIBITION OF 11β-HSD1 WITH RO5093151 FOR NON-ALCOHOLIC FATTY LIVER DISEASE: 以下備考", THE LANCET DIABETES & ENDOCRINOLOGY, vol. VOL:2, NR:5, JPN5018001972, May 2014 (2014-05-01), GB, pages 406 - 416, ISSN: 0004211110 *
ＴＨＥ ＬＩＰＩＤ, vol. ２３（１）, JPN6020005150, 2012, pages 42 - 48, ISSN: 0004350422 *
心臓, vol. ３９（２）, JPN6020005148, 2007, pages 183 - 186, ISSN: 0004350421 *
糖尿病, vol. ５４（３）, JPN6020005146, 2011, pages 172 - 174, ISSN: 0004350420 *

Also Published As

Publication number Publication date
WO2016169983A1 (fr) 2016-10-27
RU2017137262A3 (enExample) 2019-09-30
CN107530355A (zh) 2018-01-02
EP3285774B1 (fr) 2020-01-08
BR112017021586A2 (pt) 2018-07-03
MX2017013453A (es) 2017-12-07
US20180140609A1 (en) 2018-05-24
FR3035326A1 (fr) 2016-10-28
FR3035326B1 (fr) 2017-05-12
EP3285774A1 (fr) 2018-02-28
RU2017137262A (ru) 2019-05-21
CA2981933A1 (fr) 2016-10-27
AU2016251601A1 (en) 2017-11-30
KR20170139030A (ko) 2017-12-18

Similar Documents

Publication Publication Date Title
US11524930B2 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
EP3259271B1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
JP6633812B2 (ja) バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法
CN112870202A (zh) 使用甲基巴多索隆或其类似物治疗和预防肾病的方法
JP2013528198A (ja) １型糖尿病の処置
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
AU2017370003B2 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
KR20230022164A (ko) 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법
US20230218563A1 (en) Methods for treating or preventing chronic kidney disease
US20180297929A1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
JP2018513175A (ja) 非アルコール性脂肪性肝炎の予防および／または治療における（４−ヒドロキシ−２−メチル−１，１−ジオキシド−２Ｈ−ベンゾ［ｅ］［１，２］チアジン−３−イル）（ナフタレン−２−イル）メタノンの使用
TW202135811A (zh) 使用整聯蛋白抑制劑組合治療肝臟疾病
KR102784482B1 (ko) 신경퇴행성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
CA2867521A1 (en) Methods and compositions for treating arteriosclerotic vascular diseases
CN113874023A (zh) 使用奥贝胆酸诊断和治疗肝病的方法
US20230346765A1 (en) Methods of treating xanthine oxidase-related diseases with niflumic acid and derivatives thereof
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
EP2955191B1 (en) Compound, composition and method for treating and/or ameoliorating kidney disease
HK40052300A (en) Methods of treating and preventing a renal disease using bardoxolone methyl or analogs thereof
HK40011743A (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
JP2019182845A (ja) キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
HK40014768A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200925